Abstract 1,25-dihydroxyvitamin D3 11,25(OH)2D31 suppresses parathyroid hormone (PTH) gene transcription. Recent evidence suggests that retinoid X receptors are involved in 1,25(OH)2D3-mediated transcriptional events. However, little data exists for a role of retinoids in parathyroid function or in PTH expression. In the present study, we observed that all-trans-or 9-cis retinoic acid suppressed the release of PTH from bovine parathyroid cell cultures. Both retinoids were remarkably potent with significant decreases evident at 10-10 M and a maximally suppressive effect (-65%) at 10'-M. All-trans-retinol was considerably less potent in this system. The effect was not evident until 12 h, suggesting that retinoids did not affect the rapid secretion of preexisting PTH stores. PreproPTIH mRNA levels were also suppressed by retinoic acid and the retinoid potencies were similar to those observed in the secretion studies. Combined treatment with 10-6 M retinoic acid and 10-8 M 1,25(0H)2D3 more effectively decreased PTH secretion and preproPTH mRNA than did either compound alone. These data indicate that retinoic acid: (a) elicits a bioresponse in bovine parathyroid cells; (b) attenuates PTH expression at the protein and mRNA levels, and (c) acts independently of 1,25(OH)2D3 in the control of PTH expression. (J. Clin. Invest. 1994. 93:725-730.)
Introduction
It is well accepted that ionized calcium and 1,25-dihydroxyvitamin D3 [ 1, 25 (OH ) 2D3 ]' are the two main regulators of parathyroid hormone (PTH) synthesis and secretion. The action of calcium on PTH secretion is rapid (< 3 min) and that of 1,25(OH)2D3 is relatively delayed (> 6 h). In general, serum 1 . Abbreviations used in this paper: 1,25 (OH )2D3, 1,25 dihydroxyvitamin D3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PTH, parathyroid hormone; RAR, retinoic acid receptor; RXR, retinoid X receptor; VDR, vitamin D receptor.
ionized calcium is important for regulating the minute-to-minute secretion of PTH, while 1,25 (OH )2D3 is the principal factor that governs the rate of parathyroid hormone synthesis. PTH and preproPTH mRNA levels are decreased in response to 1,25 (OH)2D3 ( 1, 2) , and this response is manifested at the level of PTH gene transcription (3, 4) . Transcriptional effects of 1,25 (OH)2D3 are mediated by the vitamin D receptor (VDR) (5) . The VDR functions as a ligand-inducible transcription factor that binds to specific DNA promoter sequences termed vitamin D responsive elements present in 1,25(OH)2D3-responsive gene sequences. Importantly, recent data suggest a role for an additional receptor protein in this mechanism. In this regard, a mammalian nuclear factor is essential for high affinity binding of VDR to vitamin D responsive elements in vitro (6) (7) (8) . Further studies suggest this factor is related to the retinoid X receptors (RXRs), a newly discovered subclass of nuclear receptors that mediate cellular responses to 9-cis retinoic acid (9-1 1). RXRs form stable heterodimers with VDR in vitro (12) (13) (14) and enhance 1,25 (OH)2D3-dependent transcription in transient expression assays ( 14, 15) . Consequently, the possibility exists that retinoids and their receptors also may be involved in 1,25 (OH)2D3-mediated suppression of PTH gene expression.
There is little data concerning a role for retinoids or their nuclear receptors in the control of PTH expression or in parathyroid function. Currently, it is not known if parathyroid glands express nuclear receptors for retinoids, and there are only a few reports that describe an effect of vitamin A on PTH expression. More than 15 years ago, Chertow et al. ( 16) reported that vitamin A stimulated PTH secretion from bovine parathyroid slices, and that vitamin A elevated serum PTH in normal human males 1 h after its administration. In contrast, Frankel et al. ( 17) demonstrated that rats chronically intoxicated with vitamin A had undetectable levels of serum PTH, suggesting that hypervitaminosis A suppressed PTH secretion in vivo.
In the present study, we examined direct effects ofretinoids on PTH expression in bovine parathyroid cell culture. We show, for the first time, that retinoic acid potently inhibits PTH synthesis at the level of preproPTH mRNA in this system. The suppressive effect of retinoids was evident at physiologic concentrations and was remarkably similar to the suppression of PTH mediated by 1,25(OH)2D3. These data suggest a role for retinoids in parathyroid gland function and, specifically, in the regulation of PTH expression.
Methods
Primary cell cultures. Primary monolayer cultures of bovine parathyroid cells were prepared according to the method of MacGregor et al. (18) , with minor modifications. Briefly, bovine parathyroid glands were trimmed of extraneous fatty tissue, sliced to 0.5-mm thickness with a tissue slicer (Stadie Riggs; Thomas Scientific, Swedesboro, NJ), and placed in a 50/50 mixture of DME/Hamm's F-12 medium con-taining 2.5 mg/ml collagenase (Boehringer Mannheim Corp., Indianapolis, IN) and 0.5 mM total calcium. The suspension (1 g tissue/ 10 ml media) was agitated in a shaking water bath at 370C for 90 min and periodically aspirated through a large bore hole cut in an Eppendorf pipet tip attached to a 60-ml syringe. The digested tissue was filtered through gauze, resuspended, and washed three times with culture medium containing DME/Hamm's F-12 (50:50), 1 mM total calcium, 4% newborn calf serum, 15 mM Hepes, 100 IU/ml penicillin, 100
,ug/ml streptomycin, 5 ,qg/ml insulin, 2 mM glutamine, and 1% nonessential amino acids. Cells were plated at 80,000 cells/cm2. After 24 h, the medium was replaced with the same medium described above, with the exception that the serum was replaced with 1 mg/ml bovine serum albumin and 5 ug/ml holo-transferrin. Thereafter, this serum-free medium was replenished every 24 h.
PTH secretion. Treatment media were prepared by adding the appropriate concentration of ethanol vehicle, 1,25 (OH )2D3 or retinoids to serum-free culture media. The concentration of ethanol was always below 0.1%. Monolayers were cultured in 12-well plates and maintained in treatment media for the indicated periods oftime with media changes every 24 h. To examine PTH, the monolayers were washed three times with Dulbecco's PBS and then incubated with fresh treatment media for 3 h. Media were collected on ice, centrifuged, and supernatants were stored at -20'C for PTH analysis. The monolayers were washed with Dulbecco's PBS, dissolved in 0.1 N NaOH, and stored at -20'C for cellular protein analysis. Protein concentration was measured using a protein assay kit (Bio-Rad Laboratories, Richmond, CA). Immunoreactive PTH was assayed using antiserum CH9 as described previously ( 19 (20) . Sequential probing with multiple cDNAs was accomplished by stripping the membrane in 50% formamide, at 65°C for 3 h between hybridizations.
Results
Retinoic acid suppresses PTH secretion in bovine parathyroid cell culture. Based on the ability of RXRs and 9-cis retinoic acid to participate in selected vitamin D-mediated transcriptional events ( 14, 15, 21 previously. Therefore, we further characterized the retinoid effect with respect to time, dose, and retinoid specificity (Fig. 2) . As illustrated in Fig. 2 A, there was no statistically significant effect of retinoic acid on PTH secretion from parathyroid cells during [1] [2] [3] [4] [5] [6] h, suggesting that retinoic acid did not alter rapid secretion of preexisting stores of PTH in this system. The suppressive effect was first apparent after a 12-h treatment with retinoic acid (25% inhibition; P < 0.002) and was decreased > 60% by 72 h. Because of potential isomerization of 9-cis retinoic acid to the all-trans isomer, it is possible that all-trans retinoic acid might elicit a similar response. In the experiment shown in Fig.   2 B. we compared the dose response of various retinoid compounds on PTH secretion in this system. We noted that 9-cis retinoic acid and all-trans retinoic acid were similar and remarkably potent suppressors of PTH release with significant effects apparent at 10-10 M. A maximal effect (-65% inhibition) for both retinoids was observed at 10' M concentrations. This dose response curve is remarkably similar to that observed in retinoic acid-mediated transcription studies (10, 1 1) . In contrast, all-trans retinol was consistently less potent at affecting PTH secretion under these conditions. Significant suppression with the alcohol isomer was not observed except at 1 uM concentrations during the 72-h treatment period. transcript levels (inset). Scanning densitometry revealed a 75 and 70% reduction in the preproPTH/GAPDH ratio with 1,25(OH)2D3 and 9-cis retinoic acid, respectively. In the experiment shown in Fig. 4 , we compared the time dependence of 1,25(OH)2D3-and 9-cis retinoic acid-mediated suppression on preproPTH transcript levels in bovine parathyroid cell culture. Both compounds required approximately the same time frame to elicit their individual effects. Marked 9-cis retinoic acid, and all-trans retinol to suppress preproPTH transcript levels (Fig. 5) . As seen previously in the secretion studies (Fig. 2) , both 9-cis and all-trans retinoic acid were equally effective at decreasing steady state levels of preproPTH mRNA in bovine parathyroid cell culture. Marked suppression was evident at 10-10 M concentrations, and the acid isomers were more than 100-fold more effective than retinol in mediating the response in this system. That is, 10-6 M all-trans retinol was required to produce the same degree ofsuppression as seen with 10-8 M retinoic acid. 
Discussion
The experimental results clearly show that in bovine parathyroid cell cultures, retinoic acid is a potent inhibitor of PTH synthesis. Retinoic acid-mediated suppression is evident at the steady state level of preproPTH mRNA and is also reflected in the amount of immunoreactive PTH peptide released from the cell. Interestingly, the time course, dose response, and relative magnitude of the retinoid-mediated effect at both the PTH peptide and preproPTH mRNA levels closely parallel the inhi- (Fig. 4) ( 17) showed reduced serum PTH in rats administered high doses of retinoids suggesting that hypervitaminosis A may suppress PTH expression in vivo. That study was complicated by hypercalcemia in the vitamin A-intoxicated animals, presumably caused by the effects of vitamin A on bone and its ability to mobilize bone calcium (25) (26) (27) (28) . Thus, decreased PTH in hypervitaminosis A may be secondary to increased serum calcium caused by the action of vitamin A on bone. Importantly, our in vitro studies with bovine parathyroid cells strongly support a direct role for retinoids in the regulation ofPTH expression. We show in vitro that retinoic acid-mediated suppression of PTH occurs independent ofcalcium and independent of 1,25 (OH )2D3, the two major regulators of PTH expression. Therefore, our studies suggest that the parathyroid gland is a target organ for retinoid action and, specifically, they provide strong evidence that retinoids are involved in the synthesis of PTH.
Based on the specificity and dose response profiles, we can not distinguish between the effects of all-trans retinoic acid or 9-cis retinoic acid, but clearly the acid isoforms are 100-fold more potent than all-trans retinol. This specificity is a clear indication that the suppression observed in this report is not caused by generalized effects of these fat-soluble compounds on the in vitro parathyroid cell system. Moreover, the observation that all-trans and 9-cis retinoic acid are equipotent implies that the suppressive effect may be mediated predominantly through the RARs and not through the RXRs. This is based on the observation that 9-cis retinoic acid is specific for RXR-mediated events ( 10, 11) , while both the trans and cis isomers of retinoic acid are effective ligands for RAR-dependent mechanisms (29) . One caveat to this line of reasoning is that the parathyroid cells may express enzymes that isomerize retinoic acid, which would confound the interpretation of these data. Such isomerases are expressed in the visual system that act on retinol to regenerate the visual chromophore (30, 31 ) .
Metabolism of retinoids in the bovine parathyroid cell system may also explain why micromolar concentrations of alltrans retinol suppressed PTH secretion and PTH transcript levels. It is possible that the parathyroid cells express the enzymatic machinery required to oxidize all-trans retinol to the more active acid isoforms. Recent evidence for a cytosolic dehydrogenase that generates retinoic acid in several vitamin A-responsive tissues was described (32) . Thus, during the 72-h treatment period, micromolar concentrations of all-trans retinol may be converted to a more active form, such as retinoic acid, which then acts within the parathyroid cell to decrease PTH expression. Further studies that examine retinoid metabolism or endogenous vitamin A stores also would provide sustantive proofthat the parathyroid is an important target for the effects of retinoids in vivo.
Our results also indicate a possible therapeutic application of retinoids to the treatment of hyperparathyroidism. In the United States alone, more than 40,000 men and women each year develop end-stage renal failure. It is well established that, with progressive loss of renal mass and function, nearly all these patients develop secondary hyperparathyroidism, a pathological state characterized by an enlarged parathyroid gland and supranormal levels of serum PTH. A primary clinical target in these patients is the parathyroid gland and the control of PTH secretion. In fact, the suppressive effect of 1,25 (OH)2D3 on PTH has led to its use in the treatment of secondary hyperparathyroidism (33) . In many cases, this treatment is not absolute, since serum PTH levels are markedly lower, but still well above the normal range. Therefore, defining the role of other agents that suppress PTH secretion or synthesis may lead to the development of even more effective treatments to combat this condition. Should future studies reveal that the in vitro effects observed in this report also have relevance in vivo, then it is highly probable that with the continuing development of low toxic retinoid analogues, a new therapeutic potential may be considered in the treatment of secondary hyperparathyroidism.
